Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by saltajaon Jun 02, 2017 6:54pm
268 Views
Post# 26319271

RE:RE:RE:ok so here is what we missed I believe, From oct 26 nr

RE:RE:RE:ok so here is what we missed I believe, From oct 26 nr GoBBs,
Q4 conference call presentation slide #14:

Filed for Priority Review 

Given the rolling submission I think notice could have come anytime. Based on the links to FDA guidelines as posted on this BB it looks like Tuesday June 6 is the latest date (PLI learns on Monday). Best to not hold our breath.

IMHO
Bullboard Posts